NCT05391490View on ClinicalTrials.gov

Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2034

Conditions
Blood Cancer
Interventions
GENETIC

KCAT19 T cells

Allogeneic, cord unit derived KCAT19 T cells

All Listed Sponsors
lead

University College, London

OTHER

NCT05391490 - Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies | Biotech Hunter | Biotech Hunter